UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000007613 |
|---|---|
| Receipt number | R000008789 |
| Scientific Title | Preventing postoperative nausea and vomiting: Effect of Neurokinin-1 receptor antagonist(Fosaprepitant) |
| Date of disclosure of the study information | 2012/03/31 |
| Last modified on | 2015/03/20 11:27:57 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Preventing postoperative nausea and vomiting: Effect of Neurokinin-1 receptor antagonist(Fosaprepitant)
Acronym
Preventing postoperative nausea and vomiting: Effect of Neurokinin-1 receptor antagonist
Scientific Title
Preventing postoperative nausea and vomiting: Effect of Neurokinin-1 receptor antagonist(Fosaprepitant)
Scientific Title:Acronym
Preventing postoperative nausea and vomiting: Effect of Neurokinin-1 receptor antagonist
Region
| Japan |
Condition
Condition
postoperative nausea and vomiting
Classification by specialty
| Anesthesiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Evaluating the efficacy and tolerability of the nurokinin-1 receptor antagonists(fosaprepitant) for theprevention of the postoperative nausea and vomitting (PONV).
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
frequency of the PONV
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Blinding
Single blind -participants are blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Patients received general anesthesia for abdominal operation of gynecology assign Fosaprepitant group to Control group (ONS)in a randmized. On the day of surgery,Fosaprepitant group takes Fosaprepitant 150mg:iv 1 hours before anticipated induction of anesthesia.
Interventions/Control_2
Control group does not intervene on medicine.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 70 | years-old | >= |
Gender
Female
Key inclusion criteria
Eligible patients are between 20-70 years old who met the criteria of the American Society of Anesthesiologists(ASA) physical status of 1-3,and are scheduled for abdominal surgery of gynecology requiring an overnight hospital stay.
Key exclusion criteria
Patiens are excluded the criteria of the American Society of Anesthesiologists(ASA) physical status of over 3 neurotic disease,kidney disorder,hepatic disorder and taked antiemetic drugs.Further,excluded contraindication of Aprepitant(an anamnesis of hypersensitivity and taked Pimozide).
Target sample size
200
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yasuo Tsutsumi |
Organization
Tokushima University Hospital
Division name
Anesthesiology
Zip code
Address
Kuramoto 3-18-15,Tokushima 770-8503,Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name |
Organization
Tokushima University Hospital
Division name
Anesthesiology
Zip code
Address
TEL
088-633-7181
Homepage URL
Sponsor or person
Institute
Department of Anesthesiology,Tokushima University Hospital
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 03 | Month | 31 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 03 | Month | 09 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 05 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2012 | Year | 03 | Month | 30 | Day |
Last modified on
| 2015 | Year | 03 | Month | 20 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008789
